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CD4T  cells  play a key role  in humoral  immunity  by  providing  help  to B  cells,  enabling  effective  antibody
class  switching  and  afﬁnity  maturation.  Some  vaccines  may  generate  a poor  response  due  to  a  lack  of
effective  MHC  class  II epitopes,  resulting  in  ineffective  helper  T cell  activation  and  recall  and  consequently
poor  humoral  immunity.  It  may  be beneﬁcial  to  provide  a CD4  T  cell  helper  peptide  with  a vaccine  par-
ticularly  in  the  case  of a  poorly  immunogenic  antigen.  Such  a T cell  helper  peptide  must  be promiscuous
in  its  ability  to bind  a broad  range  of MHC  class  II alleles  due  to broad  allelic  variation  in the human
population.  We  designed  a  chimeric  MHC class  II  peptide  (TpD)  with  epitopes  from  tetanus  toxoid  and
diphtheria  toxoid,  separated  by  an  internal  cathepsin  cleavage  site.  TpD  was  capable  of  inducing  a  mem-
ory  recall  response  in peripheral  blood  mononuclear  cells  from  20/20  human  donors.  T cells  responding
to  TpD  showed  a central  memory  phenotype.  Immunization  of mice  with  a synthetic  nicotine  nanopar-
ticle  vaccine  containing  TpD  showed  that  the  peptide  was  required  for robust  antibody  production  and
resulted  in  a long  term  CD4  memory  T  cell  recall  response.
As a  pre-clinical  model  two  non-human  primate  species,  rhesus  macaques  and  cynomolgus  monkeys,
were  immunized  with  a  nicotine  nanoparticle  vaccine  and  evaluated  for an anti-nicotine  antibody
response  and  TpD  speciﬁc  memory  T cells.  We  found  that 4/4  rhesus  monkeys  had  both  sustained  anti-
body  production  and  TpD  memory  T  cells  for  the  duration  of  the  experiment  (119  days).  In  addition  30/30
cynomolgus  monkeys  dosed  with nicotine  vaccine  nanoparticles  showed  dose-dependent  antibody  gen-
eration  and  T cell  recall  response  compared  to saline  injected  controls.  In summary  we have  developed  a
potent  universal  memory  T  cell  helper  peptide  (TpD)  that  is  active  in vitro  in  human  PBMCs  and  in vivo
in  mice  and non-human  primates.
©  2014  Elsevier  Ltd.  Open access under CC BY-NC-ND license.. Introduction
CD4 T cells provide ‘help’ in stimulating B cells to mature as well
s undergo immunoglobulin class switching and afﬁnity matura-
ion, and as a result are required for development of a successful
accine.
In order to provide help CD4 T cells must recognize HLA Class II
pitopes found in the immunogen. Unfortunately not all vaccines
ave sufﬁcient HLA Class II epitopes to induce a proper T cell helper
esponse in a diverse population. As a consequence there may  be
ome value in designing a ‘universal’ helper T cell epitope to be
ncluded in the vaccine. A limiting factor for targeting a speciﬁc CD4
esponse to induce T cell help in a vaccine is the large number of
∗ Corresponding author. Tel.: +1 617 923 1400; fax: +1 617 924 3454.
E-mail address: kkishimoto@selectabio.com (T.K. Kishimoto).
ttp://dx.doi.org/10.1016/j.vaccine.2014.02.024
264-410X © 2014 Elsevier Ltd. Open access under CC BY-NC-ND license.polymorphisms in MHC  class II genes. Each individual has spe-
ciﬁc set of MHC  class II alleles, and each allele may have different
peptide-binding properties [1]. As a consequence, a universal CD4 T
cell helper peptide would have to bind promiscuously to multiple
alleles to provide broad coverage across a population. In addition,
the peptide would preferably make use of pre-existing CD4 T cell
memory to give a rapid and robust response. The concept of the
need for a ‘promiscuous’ or universal helper peptide has been stud-
ied by a number of groups. Efforts have primarily focused on de
novo designed peptides [2] or identifying peptides that provide a
recall response to epitopes in commonly administered vaccines,
such as tetanus and diphtheria toxoid (TT and DT respectively), in
previously vaccinated subjects. The latter approach has the advan-
tage of being able to validate peptide selection by assessing in vitro
recall responses using peripheral blood mononuclear cells (PBMC)
from normal healthy donors. While a broad range of potential uni-
versal epitopes have been identiﬁed for both TT and DT [3–7],
cine 3
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 considerable amount of work has focused on TT830–844 [8–10].
xperimental evidence suggests that TT830–844 can be presented
y up to ten different MHC  class II alleles [3,6], although this has
een disputed [11]. TT830–844 has been used as a helper peptide
n various animal species including mice [12–14], rats [15], rabbits
16] and rhesus macaques [17]. The predominant focus has been on
sing a helper peptide to improve a cytotoxic T lymphocyte (CTL)
esponse for treating viruses and cancer [13–15], rather than for
nhancement of humoral immunity. In one primate study, a CTL
esponse was induced to simian immunodeﬁciency virus peptides
rom Nef and Gag proteins [17]. However, only two  of eight pri-
ates demonstrated a proliferative response to the peptide. Helper
eptides have been used in several clinical studies, again primar-
ly focusing on inducing CTL responses for the treatment of human
iruses or cancer. TT830–844 has been tested in vaccines to induce
TL responses for treatment of chronic hepatitis B virus [18] and
uman immunodeﬁciency virus infection [19–21]. In addition, the
elper peptide has been used to enhance CTL responses for the
reatment of melanoma [22,23]. Those publications demonstrating
ecall response to TT830–844 report an average range of 60–75% of
ubjects responding [18,22]. However, in one report 91% of patients
hat received an immunization containing MHC  class I restricted
elanoma peptides plus TT830–844 demonstrated a recall response
o the helper peptide, but 18% that did not receive the helper pep-
ide also responded, presumably due to previous immunization
ith TT [23].
We  have rationally designed a fully synthetic nanoparticle-
ased vaccine against nicotine for smoking cessation. However
either the B cell antigen, nicotine nor the nanoparticle polymer
ontain T cell epitopes needed to provide help for B cell differ-
ntiation and antibody afﬁnity maturation. Here we describe a
universal’ memory CD4 helper peptide that was  designed and
ncluded in synthetic nanoparticle vaccines to provide promiscu-
us binding to a broad range of the most common MHC  class II
lleles in order to provide CD4 T cell help for B cell maturation and
ntibody production. We  hypothesized that inclusion of a dimeric
D4 helper memory peptide (TpD) containing both TT and DT epi-
opes linked by a cathepsin linkage site, would result in improved
ntibody responses. We  demonstrate that all 20 of tested normal
uman blood donors generated an in vitro memory recall response
o the chimeric peptide. In mice the helper peptide was  required
o for efﬁcient antibody response to a synthetic nicotine vaccine. In
ynomolgus and rhesus monkeys high levels of antibodies could be
chieved in a dose dependent fashion, with a robust memory CD4
ecall response to TpD in all animals that received sufﬁcient doses
f vaccine.
. Materials and methods
.1.  Mouse experiments
For  mouse experiments female 6–8-week-old Balb/C mice
Jackson Laboratories) were housed and handled at Vivisource
Cambridge, MA)  in accordance to Institutional Animal Care and
se Committee (IACUC) requirements. For vaccine injections, mice
ere injected subcutaneously with a single bolus of nanoparticle
reparations in PBS (50 l/limb). Mice were injected 3 times (1
rime and 2 boosts immunizations) with 2-week intervals between
mmunizations. For serum collection, blood was collected by lat-
ral tail vain bleeding 12 days after each immunization and after
hat as indicated. At the termination of the experiment, mice were
uthanized by CO2 asphyxiation and blood collected by cardiac
uncture.
For long term memory recall assays Balb/C mice were inocu-
ated on days 0, 14 and 28 with nicotine nanoparticles containing2 (2014) 2896–2903 2897
R848  and either TpD or ovalbumin 323–339 (Ova) peptide. Spleens
were harvested between 122 and 152 days after ﬁnal inoculation
and both CD4+ and CD11c+ cells were isolated directly ex vivo by
MACS cell separation system (Miltenyi, Cambridge, MA). Cells were
incubated at 37 ◦C at a 10:1 ratio (500,000 CD4 T cells to 50,000 den-
dritic cells) with 10uM peptide. Supernatants were harvested 18 h
later and assayed for IFN- by ELISA.
2.2. Non-human primate experiments
For Rhesus macaques (Macaca mulatta) experimental pro-
cedures as outlined in Harvard Medical Associates standing
committee on animal’s protocol # 04758 were followed throughout
the study. The study followed The Public Health Service (PHS) Policy
on Humane Care and Use of Laboratory Animals, and was adminis-
tered in accordance with IACUC requirements. Four, three year old
Rhesus macaques received a total of three vaccinations at 4-week
intervals. At each procedure time point, the animals were sedated
with 10 mg/kg ketamine-HCl administered intramuscularly. 1 mL
of the test substance was administered via the subcutaneous route.
Brieﬂy, the skin on the quadriceps was shaved, wiped with alcohol
and allowed to dry. The immunizing material was then adminis-
tered via a 23 gauge, 1-inch needle. The animals were monitored
and returned to their home cage when awake. The animals were
weighed when sedated for each procedure. Blood samples (in 10 mL
round bottom tubes with EDTA; used for ELISPOT) and 5 mL of
serum (used for antibody analysis) were collected at approximately
bi-weekly intervals.
For  the cynomolgus monkey study, animal welfare was  in com-
pliance with the U.S. Department of Agriculture’s (USDA) Animal
Welfare Act (9 CFR Parts 1–3). The Guide for the Care and Use
of Laboratory Animals, Institute of Laboratory Animal Resources,
National Academy Press, Washington, D.C., 1996, was  followed. The
non-clinical laboratory (MPI Research, Inc. Mattawan, MI)  study
was conducted in accordance with the United States Food and Drug
Administration (FDA) Good Laboratory Practice (GLP) Regulations,
21 CFR Part 58. MPI  Research is accredited by the Association for
Assessment and Accreditation of Laboratory Animal Care Interna-
tional (AAALAC International), and was  under guidance of IACUC.
Vaccinations with the nanoparticle vaccine and saline control were
administered by injection between the skin and underlying layers
of tissue in the thigh region of each animal. The same injection
site on each animal was used for each administration unless a
reaction at the injection site indicated that another site must be
used. All injection sites were marked and identiﬁed throughout
the course of the study. The dose was administered by bolus injec-
tion. Monkeys were immunized (N = 10 per group) on days −78
and −48 with a combined pediatric diphtheria/tetanus toxoid vac-
cine, and then immunized on days 1, 29, and 57 with saline, or
escalating doses of 1 mL  of nanoparticle vaccine at 0.5, 2.0, 8.0 and
16.0 mg/mL. Blood was  collected on days shown, prior to immu-
nization (day 1) and then on days 29, 57, 85, 113, and 141 to test
for anti-nicotine antibodies. Peripheral blood was collected on day
85 for T cell recall analysis (3 mL)  and PBMC isolated by percoll
centrifugation.
2.3. Peripheral blood mononuclear cell preparation
Brieﬂy, human peripheral blood mononuclear cells (PBMCs)
were isolated from normal human donors (Research Blood Com-
ponents, Cambridge, MA). Blood was  diluted 1:1 in phosphate
buffered saline and then 35 mL  overlaid on top of 12 mLs Ficoll-
Paque premium (GE Healthcare, Pittsburgh, PA) in a 50 mL
centrifuge tube. Tubes were spun at 1400 RPM for 30 min, and the
transition phase PBMCs collected, diluted in PBS with 2% fetal calf
serum and spun at 1200 rpm for 10 min. Cells were re-suspended
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score is a predictor of higher afﬁnity binding. Scores higher than ten
are not shown. Both T and D epitopes are predicted to have high898 C.C. Fraser et al. / Vac
n cell freezing media (Sigma–Aldrich, St. Louis, MO)  and immedi-
tely frozen at −80 ◦C. For long term storage, cells were transferred
o liquid nitrogen. For rhesus monkey PBMC isolation the protocol
as the same except 5 mL  of blood was collected and processed.
or cynomolgus monkey PBMC, 3 mL  of blood was processed, buffy
oat was collected and overlaid on 60% Percoll (GE Healthcare),
entrifuged 30 min  at 1755 rpm, washed and frozen as described
bove.
.4. Tissue culture and ﬂow cytometry
Frozen PBMC were thawed (37 ◦C water bath), re-suspended in
BS 10% FCS, spun down and re-suspended to 5 × 106 cells/mL in
issue culture media (RPMI), supplemented with 5% heat inactiv-
ted human serum (Sigma–Aldrich), l-glutamine, penicillin and
treptomycin, (Gibco, Grand Island, NY). For memory T cell recall
esponse assays, cells (0.6–1.0 mL)  were cultured in 24-well plates
ith 4 M peptide (GenScript) at 37 ◦C 5% CO2 for 2 h. One L
f 1000× Brefeldin A (BD, San Jose, CA) per mL  of culture media
as then added and cells returned to a 37 ◦C incubator for 4–6 h.
ells were then incubated at 27 ◦C, 5% CO2 for 16 h. Detection
f activated memory T cells was performed by incubation of
ells with ﬂuorochrome conjugated antibodies: CD4-FITC, CD45RA-
E, CD62L-Cy7PE, CD45RO-PerCPCy5.5, CCR7-PB (Biolegend, San
iego, CA) and CD45RA-PE, CD4-APCCy7, CD27-V500 (BD) fol-
owed by membrane permeabilization and ﬁxing (BD). Expression
f intracellular cytokines was detected using interferon--APC and
NF--APC (BD). 200,000–500,000 cells were then analyzed using
 either a FACSCaliber (BD) or FACSCanto ﬂow cytometer, and Cel-
quest or Diva (BD) software.
.5.  ELISPOT assay
For  the ELISPOT assay 96 well ﬁlter plates (Millipore, Billrica,
A) were coated 18 h prior to use with PBS containing 15 g/mL
nterferon- capture antibody (Mabtech, Mariemont, OH) at 4 ◦C.
he plates were coated for 2 h at room temperature with com-
lete culture media to block non-speciﬁc binding. PBMC were
iluted to 3–5 × 106 cells/mL and 100 L plated per well on the
ntibody pre-coated elispot plates with or without addition of
5 M peptide (TpD). Positive control wells were stimulated with
0 g/mL phytohemagglutinin (PHA (Sigma). After 18 h of incuba-
ion at 37 ◦C, elispot plates were washed in PBS containing 0.05%
ween 20 (Fisher Scientiﬁc, Waltham, MA), followed by incuba-
ion with 100 L biotinylated anti-IFN- secondary antibody for
 h at room temperature. Elispot plates were then washed 3 times
n PBS/tween-20 buffer (Fisher Scientiﬁc) and three times in PBS.
FN- spots were developed using 100 L per well 3-amino-9-
thylcarbazole (Sigma), dimethylformamide (Sigma) and hydrogen
eroxide (Sigma) in acetate buffer. After 5–10 min  of development,
lates were thoroughly washed in water and dried. Interferon-
ositive elispot counts were scored by an outside vendor (ZellNet,
ort Lee, NJ). Statistical analysis was performed in Excel, and data
lotted using SigmaPlot.
.6.  Nicotine nanoparticle synthesis
The nicotine nanoparticle is generated using a double emulsion
rocess. A primary water-in-oil emulsion is formed by high shear
ixing of a primary aqueous solution (TpD in 60% lactic acid) and
n organic solution containing polylactic acid-polyethylene glycol-
icotine (PLA-PEG-nicotine), poly(lactic-co-glycolic acid)-R848,
nd PLA in dichloromethane at controlled speeds and tempera-
ures. The double emulsion (water-in-oil-in-water) is formed by
dding a secondary aqueous solution (phosphate buffer with 10%
olyvinyl alcohol) to the primary emulsion and high shear mixing2 (2014) 2896–2903
at  controlled speeds and temperatures for a ﬁxed duration. The
PVA and phosphate buffer solution form the continuous phase.
The nanoparticles are formed and hardened by evaporation of the
organic solvent (dichloromethane) from a well-stirred suspension.
As the solvent is removed from the emulsion, the polymeric matrix
condenses and hardens into nanoparticles. The nanoparticles are
further washed in PBS, and the ﬁnal nanoparticle suspension is
passed through a 0.2 m ﬁlter.
2.7. ELISA protocol
ELISA  plates were coated with 100 L per well of a polylysine–
nicotine conjugate in PBS and incubated overnight at 4 ◦C. Plates
were washed 3 times in wash buffer (PBS/0.05%Tween20) (Sigma)
and blocked with 300 L per well of 1% casein (Fisher Scientiﬁc) in
PBS for 2 h at room temperature. Plates were washed as described
above, serum samples were serially diluted 3-fold down the plate,
and plates left for 2 h at room temperature. Plates were washed 3
times in wash buffer and 100 L detection antibody was added to
each well (for mouse samples HRP-conjugated rabbit anti-mouse
IgG (Jackson Immuno Research,West Grove, PA), for non-human
primate samples HRP-conjugated goat anti-monkey IgG (Abcam,
Cambridge) and incubated for 1 h at room temperature. Plates were
then washed 3 times in wash buffer and incubated for 10 min in
the dark with 100 L per well of a TMB  substrate solution (BD). The
enzymatic reaction was  stopped with 50 L per well of 2 N H2SO4.
Optical density was  read immediately after adding stop solution
on a Versamax plate reader (Molecular Devices, Sunnyvale, CA) at
450 nm with subtraction at 570 nm.  Data analysis was done using
SoftMax Pro v5.4 (Molecular Devices) and the half maximum values
(EC50) determined to calculate antibody titers for each sample.
3.  Results
3.1. Universal helper peptide design and predicted class II
coverage  and reactivity
We  screened candidate epitopes for in silico predicted broad
HLA class II allele cross reactivity and high afﬁnity binding using the
immune epitope data base (IEDB) CD4 T cell prediction tool [24,25].
A chimeric TT/DT epitope was  designed that ﬁt these criteria. We
hypothesized that inclusion of two  epitopes that would induce a
CD4 memory helper T cell response in vaccinated individuals may
provide an advantage over individual peptides. A cathepsin cleav-
age site, either pmglp or kvsvr [26] was  introduced between the
epitopes with the prediction that it would provide more efﬁcient
processing when taken up by antigen presenting cells. Pmglp was
designed to be a selective cathepsin S substrate whereas kvsvr is a
less selective cathepsin S, B and L substrate. Individual DT (D) and
TT (T) peptides were generated (Fig. 1A) as well as a chimeric TD
peptide without a cathepsin cleavage site. In addition, two  chimeric
peptides containing the pmglp or the kvsvr cathepsin cleavage site
(TpD and TkD respectively) were also generated. The predicted
reactivity of individual and chimeric peptides to 25 MHC  class II
alleles, as well as predicted binding afﬁnity, and allele frequency
are shown in Fig. 1B. The combined frequency of this set of alleles
is predicted to have greater than 99% population coverage [25]. The
predicted consensus of several algorithms is shown, where a lowerafﬁnity binding primarily across HLA-DRB1, with some binding to
DP and DQ alleles. Interestingly combining the two peptides with a
cathepsin linker in some cases alters the predicted binding afﬁnity,
for example HLA-DQA1*0301-DQB*0302.
C.C. Fraser et al. / Vaccine 3
Fig. 1. Peptide sequence and computational analysis of predicted afﬁnity to 25 HLA
Class II alleles. (A) Individual epitopes from tetanus toxoid (T), diphtheria toxoid (D),
and chimeric peptides with cathepsin cleavage sites TpD (pmglp) and TkD (kvsvr), or
without a cleavage site (TD). (B) Computational analysis using the Immune Epitope
Data Base (IEDB) T cell epitope prediction tool for individual epitopes of chimeric
epitope  TpD. Lower consensus score predicts higher afﬁnity, values >10 are not
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titers (Fig. 4C). Increasing the amount of TpD during immuniza-hown.
.2. Chimeric peptide TpD shows a recall response in PBMC from
ultiple  donors, and induces activation of cells with a CD4 central
emory phenotype
We  analyzed peripheral blood mononuclear cells (PBMC) from
0 individual donors for the ability to activate T cells with a CD4
emory phenotype. A representative example from one donor
s shown in Fig. 2A. Individual tetanus (T) and diphtheria (D)
eptides showed limited induction of CD4 + CD45RAlowCD62L+
ells expressing IFN- compared to a non-stimulated (NS) control
0.04% and 0.08% vs. 0.01% respectively). The chimeric peptide with
o cleavage site (TD) and the peptide with the kvsvr cathepsin
leavage site (TkD) showed slightly more cells expressing IFN-
0.32%). However the peptide with the pmglp cathespsin cleav-
ge site (TpD) induced a superior response (1.28%), 4-fold higher
han the chimeric peptide with no cleavage site. We  went on to
nalyze PBMC from 20 donors (Fig. 2B) and found that we  could
ot detect a speciﬁc response in most cases using either indi-
idual T (2/20 donors) or D (7/20 donors) peptides. More donors
esponded to the chimeric TD peptide (15/20) but all 20 donors
howed a recall response to the TpD chimeric peptide. The percent-
ge of CD4 + CD45RAlowCD62L+ cells expressing IFN- normalized
o a non-stimulated control for each of the peptides is shown in
ig. 2B. In addition to providing the highest percentage of respon-
ers, the TpD peptide induced the highest levels of IFN- among2 (2014) 2896–2903 2899
all  peptides tested. Interestingly TkD had diminished activity com-
pared to TpD, suggesting that the kvsvr cleavage site may  be
detrimental.
We next evaluated the type of memory cells stimulated by TpD.
Central memory cells, thought to be the most effective at generat-
ing a recall response, are CD4 + CD45RAlowCD45RO + CD27 + CCR7+
[27] and express multiple cytokines including IFN- and TNF-
 [4], whereas effector memory cells are CD4 + CD45RAlow
CD45RO+/−CD27-CCR7-. Multicolor ﬂow cytometry analysis sug-
gested that the cells responding to TpD express a phenotype of
central memory T cells (Fig. 2C). We next addressed if the mem-
ory cells favored a Th1 or Th2 phenotype upon activation. Memory
T cells can be divided based on differential chemokine receptor
expression into subsets that will produce either the Th1 cytokine
IFN-, or Th2 cytokine IL-4, on activation [28,29]. We analyzed four
separate donors and found that individual T and D peptides, as
well as chimeric peptides induced expression of IFN- in more
memory T cells than IL-4, suggesting a bias toward a Th1 sub-
set (Fig. 2D). Based on these characteristics TpD was  selected as
the memory T helper stimulating peptide for a nanoparticle based
vaccine.
3.3. TpD is required for generation of an antibody response in
nicotine  nanoparticle vaccinated mice
PLGA/PLA nanoparticles have been useful vehicles for vac-
cine development. We designed a nanoparticle vaccine carrying
nicotine as the B cell antigen (Fig. 3). The components of the
nanoparticle include: PLA-PEG-Nicotine, which is a block copoly-
mer with nicotine covalently bound to the free end of PLA-PEG;
the adjuvant R848 linked to PLGA, and the memory T cell helper
antigen TpD (Fig. 3). To assess the contribution of TpD, nanopar-
ticles were also generated that lacked TpD. As an initial test for
efﬁcacy, we  immunized mice with nanoparticles containing or lack-
ing TpD (Fig. 4). Mice were immunized on days 0, 14, 28 and 169. The
nanoparticle containing TpD induced robust anti-nicotine antibody
titers, whereas nanoparticles lacking TpD showed no detectable
antibody response (Fig. 4A). Antibody levels increased with each
boost, particularly after the third boost on day 169, 141 days after
the previous immunization, suggesting helper T cell memory was
long lived.
To  further assess long-lived T cell memory, we immunized
mice on days 0, 14 and 28 with nicotine nanoparticles contain-
ing R848 and either TpD or ovalbumin 323–339 (Ova) peptide
(Fig. 4B). Spleens were harvested 122–152 days after ﬁnal inoc-
ulation and either not stimulated, or stimulated ex vivo with TpD
or Ova peptide. Supernatants were harvested after 18 h and eval-
uated for IFN- levels. In TpD immunized mice, IFN- secretion
was not detectable when splenocytes were non-stimulated or chal-
lenged with the Ova peptide. In contrast IFN- was detected at
signiﬁcant levels when splenocytes were stimulated with TpD. Con-
versely, in Ova immunized mice only the Ova peptide was  able
to induce a response. The data suggests that TpD, when delivered
in a nanoparticle, is able to provide long term CD4T cell memory
and can function on re-challenge to provide a boost in a vaccine
response.
In order to evaluate the dose-dependent effect of helper peptide
on anti-nicotine antibody titers in vivo, we designed an exper-
iment using limiting levels of TpD. Mice were immunized on
days 0, 14 and 28, and on day 46 serum analyzed for antibodytion resulted in elevated anti-nicotine antibody titers, suggesting
that the magnitude of antibody response is helper peptide depen-
dent.
2900 C.C. Fraser et al. / Vaccine 32 (2014) 2896–2903
Fig. 2. Characterization of an in vitro PBMC memory T cell recall assay using ﬂow cytometry. (A) Representative example from a single blood donor. PBMC were stimulated
with different peptides overnight and then evaluated for memory T cell activation. Intracellular IFN- and CD62L expression, gated on CD4 + CD45RAlow cells are shown. (B)
Percent  memory T cells responding to various peptides indicated (% CD62L + IFN-+ in a CD4 + CD45RAlow gate) for 20 individual PBMC donors. (C) Further characterization of
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y  staining for intracellular TNF-. (D) Expression of Th1 (IFN-) or Th2 (IL-4) cy
umbers per 7.5 × 104 CD4 + CD45RAlow cells collected by ﬂow cytometry (events)
.4. MHC  class II peptide TpD generates a robust CD4 memory T
ell  recall response in nanoparticle vaccine immunized
on-human primates
We  further investigated TpD activity in non-human primate pre-
linical models. Data from rhesus monkeys immunized on days
, 28, and 56 with escalating doses of nicotine nanoparticles are
hown in Fig. 5. As expected no anti-nicotine antibody titers were
een two weeks prior to immunization or at the time of the ﬁrst
mmunization (Fig. 5A). Antibodies were detectable after the ﬁrst
mmunization, and increased signiﬁcantly after the second and
hird immunization. Titers were variable at the lowest dose (0.3 mg)
nd plateaued at the 0.9 mg  dose. Analysis of CD4 T cell recall
esponses showed detectable levels of TpD responding cells at the
owest dose, (Fig. 4B) but not prior to immunization. All 4 monkeys
ested showed helper T cell responses. There was not a clear dose
esponse, as expected given the small number of animals studied
N = 1 per group). T cell recall responses were detectable 63 days
Fig. 3. Schematic representation of nicotine nanoparticle structure.ory T cells are CD4 + CD45RAlowCD45RO + CD27 + CCR7+. Activation was evaluated
e in central memory T cells stimulated by different peptides. CD62L + IFN-+ cell
own. N = 4 donors per group.
after the last immunization, suggesting memory T cells were being
generated.
We next studied TpD activity in a larger cohort of cynomolgus
monkeys (N = 50) immunized with nicotine nanoparticles and eval-
uated them for both anti-nicotine antibody titers and T cell recall
responses (Fig. 6). Cynomolgus monkeys were pre-immunized on
days −78 and −48 with a combined pediatric diphtheria/tetanus
toxoid vaccine, and then immunized on days 1, 29 and 57, and
85 with the nicotine nanoparticle vaccine. Saline treated monkeys
were negative for anti-nicotine titers at all time points, but all other
monkeys at all doses were positive (Fig. 6A). The results showed a
dose dependent escalation in antibody response plateauing at the
8 mg  nanoparticle dose. The titers persisted until the last day of
analysis (day 141). Peripheral blood was collected on day 85 for T
cell recall analysis (Fig. 6B). Each of the ten primates dosed with 2.0,
8.0 and 16 mg  of vaccine showed a positive dose escalating T cell
recall response (N = 30/30 total) compared to saline injected con-
trols. Additionally, 6/10 monkeys immunized with the lowest dose
of 0.5 mg  gave a positive recall response to stimulation with TpD
(Fig. 6B). In summary, all cynomolgus monkeys immunized with
the three highest doses of nicotine nanoparticles showed a posi-
tive memory T cell recall response to TpD, demonstrating that TpD
was presented in vivo by cynomolgus MHC  Class II molecules and
generated a peptide-speciﬁc T cell recall response.
4. Discussion
Synthetic vaccines have potential advantages with respect to
antigen (or epitope)-speciﬁcity, safety, and ease of manufacturing.
We have recently developed a self-assembling synthetic vaccine
particle (SVP) technology which enables surface display of B cell
haptens, such as nicotine, and encapsulation of potent TLR ago-
nists. The nano-sized particles directly ﬂow through lymphatics
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Fig. 4. In vivo evaluation of TpD peptide activity in nicotine nanoparticle immunized
mice.  (A) Anti-nicotine antibody titers in nanoparticle immunized mice. Mice (N = 5
per group) were immunized on days 1, 14, 28 and 169. Results for all dates analyzed
post  immunization are shown. (B) Balb/C mice were inoculated on D0, 14 and 28
with nanoparticles containing R848 and either TpD or Ova peptide. Spleens were
harvested between 122 and 152 days after ﬁnal inoculation, and both CD4+ T cells
and CD11c+ dendritic cells isolated. Cells were incubated at a 10:1 ratio (500,000 CD4
T cells to 50,000 DCs) with 10 M peptide: (1) speciﬁc to inoculum (2) non-speciﬁc
to  inoculum. Supernatants were harvested 18 h later and assayed for IFN- by ELISA.
Number of TpD NP inoculated mice assayed = 5. Number of Ova NP inoculated mice
assayed = 3. (C) Balb/C mice (N = 5/group), were immunized with nanoparticles con-
t
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Fig. 5. Antibody titers and memory T cell recall assays in four rhesus monkeys
vaccinated  with nicotine nanoparticles. (A) Blood was collected 14 days prior to
immunization and then every 2 weeks after the ﬁrst immunization, up to 17 weeks
(day 119). Monkeys were immunized on days 1, 28, and 56 with escalating doses of
vaccine at 0.3, 0.9, 2.7, and 8.1 mg/mL in 1 mL. (B) Blood was collected at the time
shown (5 mL), and PBMC isolated by Ficoll centrifugation. At each time point of col-
lection cells were plated in anti- IFN- coated elispot plates with or without TpD
peptide.  Values shown are normalized to non-stimulated controls and representaining R848 and nanoparticles containing nicotine plus TpD (peptide), or nicotine
lone (no peptide). Immunizations were performed on days 0, 14 and 28, and blood
ollected on day 46 to evaluate anti-nicotine antibody titers.
nto lymph nodes, where they can be endocytosed and processed by
PCs [30]. However a potential limitation of synthetic vaccines, and
ven some recombinant protein vaccines, is the lack of sufﬁcient T
ell epitopes to drive robust antibody responses. In this paper, we
escribe the design and demonstrate the utility of a ‘universal’ T
ell helper peptide (TCHP) that can provide CD4 T cell help for B
ell differentiation and antibody afﬁnity maturation across a broad
opulation.
We have taken advantage of new and improved in silico pre-
iction tools to screen peptides for broad and high afﬁnity MHC
lass II binders. This approach has proven useful for screening large
umbers of potential epitopes from naturally occurring pathogen
roteins, such as tetanus toxoid and diphtheria toxoid, to design
etter TCHPs. We  created chimeric peptides based on complemen-
ary peptide epitopes that together provided broad coverage of
HC class II alleles. In order to improve the probability that a
himeric peptide would get processed properly for presentation
n MHC  class II protein, we included a synthetic cathepsin cleavage
ite between the selected TT and DT epitopes [26]. One advantage
f using TT and DT derived epitopes is that most people have been
reviously vaccinated with DT and TT, and therefore are likely to
ave pre-existing T cell memory. This enabled us to validate peptide
andidates by screening them for the ability to induce a memory cell response in normal peripheral blood donors. We  assessed
D4 memory T cells by ﬂow cytometry for cell surface markers
nd induction of cytokine expression. We  found that 20/20 donors
esponded to the chimeric peptide TpD with a synthetic cathepsinnumber  of spots per 1 × 106 PBMC.
S cleavage site. Individual peptides alone showed fewer numbers
of cells responding in fewer numbers of subjects. The frequency of
responders to individual peptides (T and D, 10% and 35% respec-
tively) was lower than that reported by others, perhaps due to the
use of a different assay [3–11]. Interestingly the recall response to
the chimeric peptide (TD) was greater than the sum of the response
to the individual epitopes. Memory T cells can be characterized
as effector or central memory cells by cell surface markers (CD4,
CD45RA, CD45RO, CD27, CCR7) and cytokine expression (IFN-,
TNF- and IL-4) [27–29]. Central memory T cells are thought to
give a faster and better response to epitope challenge than naïve T
cells. Further characterization showed that the T cells responding
to TpD had cell surface markers and cytokine expression consistent
with central memory CD4 cells. Based on these results we selected
TpD for nanoparticle vaccine formulation, and evaluation in mouse
and primate animal models.
We  used a fully synthetic nanoparticle vaccine against nicotine,
as a model system to test the activity of the TpD peptide. Studies
in mice demonstrated that TpD was both necessary and sufﬁcient
for the ability to induce a robust anti-nicotine antibody response.
Nanoparticles lacking TpD induced little or no antibody production,
while TpD-containing nanoparticles induced antibody titers which
increased with each successive boost. In particular, a boost admin-
istered at day 169, 141 days after the last immunization, induced
a 19-fold increase in antibody titer, indicating that TpD induced
long term memory T cells. This was conﬁrmed by assessment of
in vitro antigen-speciﬁc T cell recall to TpD using lymphocytes from
immunized mice. Positive results achieved with the mouse studies
prompted us to study more relevant nonhuman primate models,
initially with a small cohort of 4 rhesus monkeys, and subsequently
2902 C.C. Fraser et al. / Vaccine 3
Fig. 6. Antibody titers and memory T cell recall assays in nicotine nanoparticle vac-
cinated cynomolgus monkeys. (A) Monkeys were immunized (N = 10 per group) on
days 1, 29, and 57 with saline, or escalating doses of 1 mL  vaccine at 0.5, 2.0, 8.0 and
16.0 mg/mL. Blood was  collected on days shown, prior to immunization (day 1) and
then on days 29, 57, 85, 113, and 141 to test for anti-nicotine antibodies. (B) Periph-
eral  blood was  collected on day 85 for T cell recall analysis (3 mL)  and PBMC isolated
by percoll centrifugation. PBMC were plated in anti- IFN- coated elispot plates with
or without TpD peptide. Values shown are normalized to non-stimulated controls
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in humans, and is potent in generating a recall response in micend represent number of spots per 1 × 107 PBMC.
ith a large cohort of 50 cynomolgus monkeys previously immu-
ized with a DT and TT vaccine. Both studies were designed to
rovide an assessment of antibody and T cell help data over an
xtended period of time. Monkeys were from an outbred popula-
ion, so their MHC  class II alleles are variant and therefore a good
odel to test the ‘universality’ of TpD. Rhesus monkeys immunized
ith the nicotine nanoparticle produced sustained antibodies in a
ose-dependent fashion, and T cell recall for over 4 months. The
ynomolgus monkeys also showed a robust and dose dependent
ntibody response to a nicotine nanoparticle vaccine. All cynomol-
us monkeys (30/30) immunized with the three highest doses of
accine showed a positive memory T cell recall response to TpD,
hile those immunized with the lowest dose showed 6/10 respon-
ers. It is likely that the low responder numbers at the lowest dose
as a function of dose rather than MHC  class II allele distribution.
Alexander et al. described a de novo designed non-naturalan-DR epitope peptide (PADRE) that binds promiscuously to com-
on  HLA-DR alleles [2]. The PADRE peptide has been tested in a
umber of clinical trials. BCR-ABL peptides linked to PADRE and2 (2014) 2896–2903
co-administered  with GM-CSF to patients with chronic myeloid
leukemia elicited a PADRE-speciﬁc recall response in 14 of 14
subjects tested [31]. PADRE peptide admixed with MAGE3 pep-
tide in incomplete Freunds adjuvant administered to melanoma
patients elicited detectable but low levels of PADRE-reactive effec-
tor cells in 7 of 9 subjects [32]. PADRE peptide and WT-1, Muc-1,
and proteinase-3 CTL epitopes admixed with CpG oligonucleotides
in montanide and administered to patients with acute myeloid
leukemia and multiple myeloma induced an increase in PADRE-
reactive effector T cells in all subjects, although these T cells showed
an apparent defect in IL-2 secretion [33]. In contrast, a DNA vaccine
encoding 21 HIV-speciﬁc CTL epitopes and PADRE was  tested in 42
healthy volunteers and elicited only one positive recall response to
PADRE as measured by ELISpot [34]. Finally, autologous dendritc
cells pulsed with the PADRE elicited an ex vivo recall response to
PADRE in 10 of 18 subjects in one study [35] and low level responses
in another study [36]. Not surprisingly, the efﬁcacy and universal-
ity of the PADRE peptide may  be dependent upon the context in
which the peptide is administered, such as dose, regimen, route,
adjuvant, and form (free peptide, linked peptide, DNA-encoded, or
pulsed DCs). One of the potential advantages of using a universal T
cell helper peptide based on TT and DT is that pre-existing CD4 T
cell memory to TpD from prior immunization with DT and TT may
confer an advantage for a TpD-containing nanoparticle vaccine by
generating a larger pool of antigen-speciﬁc T cells that can provide
faster and more efﬁcient help to B cells in a secondary challenge
[37–39].
In addition CD4 memory T cells have several functional char-
acteristics that facilitate a more robust response to antigen. For
example, CD4 memory T cells have a lower threshold for activa-
tion by antigen than naïve cells and show polarized differentiation
to speciﬁc T cell subsets (e.g. Th1, Th2, Th17, and T follicular
helper (Tfh) subsets), and multi-cytokine expression (e.g., TNF-,
IL-2 and IFN-) [40]. In particular, CXCR5 expressing memory CD4
cells have been found to provide accelerated help to B cells, per-
haps due to their ability to localize to B cell follicles [41]. Overall
the data suggests that the existence of CD4 memory T cells will
be beneﬁcial in producing a more rapid and robust induction of
antibody production. As a result there may be an advantage in
targeting memory T cell activation to enhance a response in vac-
cines.
It was originally hypothesized that conjugate vaccines would
beneﬁt from pre-existing memory against the carrier, but surpris-
ingly, it was  found that prior vaccination with the carrier (e.g.
TT or DT) actually inhibited the antibody response to the hapten
conjugate [42]. This phenomenon, termed epitope-speciﬁc sup-
pression or epitopic suppression [42–45], also extends to haptens
conjugated to virus-like particles [46]. While both T cells and B
cells have been implicated in the mechanism of epitope-speciﬁc
suppression, the inhibitory effect appears to be largely due to
competition with pre-existing carrier-speciﬁc B cells and antibod-
ies [47]. Importantly, epitope-speciﬁc suppression observed with
gonadotropin releasing hormone (GnRH) peptide conjugated to DT
could be bypassed by conjugating GnRH to a T cell helper peptide
derived from DT [48]. These results suggest that epitope suppres-
sion is restricted to memory B cell epitopes not memory T cell
epitopes. Thus we  expect that that nanoparticle vaccines containing
TpD peptide would have the beneﬁt of leveraging pre-existing CD4
memory T cells without invoking B cell-mediated epitope-speciﬁc
suppression.
In conclusion we have developed a chimeric MHC  class II mem-
ory recall peptide, TpD that gives broad MHC  class II coverageand non-human primates. It is possible that this will be a valuable
tool for providing enhanced responses against poorly immunogenic
vaccines.
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